Johnson & Johnson Shares Approach Record Highs Amid Potential Major Division Sale
New York, Saturday, 12 September 2026.
Johnson & Johnson’s market valuation topped $640 billion on September 12, 2026, driven by strong trading performance and reports of a potential $20 billion sale of its orthopedics division.
Market Performance and Valuation Metrics
Johnson & Johnson shares demonstrated significant resilience during the trading session on September 12, 2026, reaching an intraday high of $270.39 before consolidating [2]. The stock closed at $266.20, reflecting a slight decrease from the previous market close of $266.35, calculated as a change of -0.056 percent [1][2]. Institutional investors are closely monitoring this price action as the healthcare giant’s market capitalization reached $640.12 billion, solidifying its position as a key barometer for defensive sector strength [2]. The company’s price-to-earnings ratio stands at 30.78, indicating investor confidence in future earnings potential despite broader macroeconomic shifts [2]. Current trading levels remain near the 52-week high of $281.07, which was recorded on September 2, 2026 [1].
Strategic Divestiture Talks
Market attention has intensified following reports that Apollo Global Management is in negotiations to acquire Johnson & Johnson’s DePuy Synthes orthopedics unit [2]. This potential transaction is estimated to value the unit at approximately $20 billion, representing a strategic shift for the healthcare holding company [2]. [alert! ‘Deal completion uncertain as negotiations are ongoing’] Such a divestiture aligns with the company’s broader strategy to pivot toward high-end MedTech growth, with a specific focus on the cardiovascular segment [2]. The organization operates through Innovative Medicine and MedTech segments, leveraging a diversified business model to withstand economic cycles [2][3]. This structure includes pharmaceuticals, medical devices, and consumer products, covering areas such as neuroscience, oncology, and surgical solutions [3][5].
Analyst Outlook and Trading Data
Analyst sentiment remains positive, with HSBC increasing its price target for Johnson & Johnson stock from $290 to $320 on September 9, 2026 [2]. Pre-market trading data from September 11, 2026, showed the stock trading at $267.38, indicating early investor interest ahead of the session [4]. The company maintains a dividend yield of 2.02%, with a dividend amount of $5.36 per share [1]. Historically, Johnson & Johnson is recognized as a long-term dividend stock, having maintained payouts through major economic downturns including the 2008 financial crisis and the COVID-19 pandemic [2]. Investors can track these movements through various brokerage platforms offering real-time quotes and market data [2][4].